Abstract
Roberti et al. [1] have recently reported on the successful immunomodulating treatment with simultaneously administered low-dose interleukins (ILs)-4, -10, and -11 in the treatment of psoriasis vulgaris. This treatment is an example of therapies based on the Physiological Regulation Medicine concepts.
Physiological Regulation Medicine represents the most up-to-date integration of low-dose medicine with the innovative therapeutic concept of restoring physiology through activated low dose of communicating molecules such as hormones, neuropeptides, interleukins, and growth factors. The low-dose preparation method, called sequential kinetic activation (SKA), seems to make communicating molecules more effective, providing a biofeedback mechanism capable of restoring the psyco-neuro-immuno-endocrine homeostatic balance [2-5].
This concept represents the "functional core" of low-dose medicine. Thanks to SKA technology (the "technical core" of low-dose medicine), it is now possible to use lower doses of communicating molecules (in the range of pg/mL) with therapeutic results that are apparently comparable with those induced by high concentrations but with reduced side effects as demonstrated by both preclinical and clinical studies [1, 5].
This innovative approach enables the provision of synergic, effective, and safe molecules that are the cornerstone of low-dose medicine.